Immuneering Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Immuneering Corporation (IMRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 266.69 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 257.41K shares, a 23.70% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 9.28K shares, a 89.00% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 76.96K shares.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 369.43K shares, a 16.11% decline from fiscal 2024.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 440.39K shares, a 26.32% increase from fiscal 2023.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 348.63K shares, a 18.88% decline from fiscal 2022.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 429.78K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 257.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 266.69K shares 10-Q · filed 2026-08-05 | 266.69K shares derived: sum of 3 quarters · filed 2026-08-05 | 343.65K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 9.28K shares 10-Q · filed 2026-05-15 | 9.28K shares derived: sum of 2 quarters · filed 2026-05-15 | 86.24K shares derived: sum of 3 quarters · filed 2026-05-15 | 294.33K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 76.96K shares derived: sum of 2 quarters · filed 2026-03-06 | 285.05K shares derived: sum of 3 quarters · filed 2026-03-06 | 369.43K shares 10-K · filed 2026-03-06 |
| 2025-09-30 | 76.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 285.05K shares derived: sum of 2 quarters · filed 2025-11-12 | 369.43K shares 10-Q · filed 2025-11-12 | 608.68K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 208.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 292.47K shares 10-Q · filed 2025-08-13 | 531.72K shares derived: sum of 3 quarters · filed 2025-08-13 | 531.72K shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 84.37K shares 10-Q · filed 2025-05-05 | 323.63K shares derived: sum of 2 quarters · filed 2025-05-05 | 323.63K shares derived: sum of 3 quarters · filed 2025-05-05 | 352.65K shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 239.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 239.25K shares derived: sum of 2 quarters · filed 2025-03-20 | 268.28K shares derived: sum of 3 quarters · filed 2025-03-20 | 440.39K shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 29.02K shares derived: sum of 2 quarters · filed 2024-11-13 | 201.14K shares 10-Q · filed 2024-11-13 | 334.40K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 29.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 201.14K shares 10-Q · filed 2024-08-06 | 334.40K shares derived: sum of 3 quarters · filed 2024-08-06 | 338.53K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 172.12K shares 10-Q · filed 2024-05-07 | 305.38K shares derived: sum of 2 quarters · filed 2024-05-07 | 309.51K shares derived: sum of 3 quarters · filed 2024-05-07 | 350.79K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 133.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | 137.39K shares derived: sum of 2 quarters · filed 2024-03-01 | 178.67K shares derived: sum of 3 quarters · filed 2024-03-01 | 348.63K shares 10-K · filed 2024-03-01 |
| 2023-09-30 | 4.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 45.41K shares derived: sum of 2 quarters · filed 2023-11-09 | 215.37K shares 10-Q · filed 2023-11-09 | 368.36K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 41.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 211.24K shares 10-Q · filed 2023-08-03 | 364.22K shares derived: sum of 3 quarters · filed 2023-08-03 | 613.62K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 169.96K shares 10-Q · filed 2023-05-04 | 322.94K shares derived: sum of 2 quarters · filed 2023-05-04 | 572.34K shares derived: sum of 3 quarters · filed 2023-05-04 | 577.22K shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 152.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 402.38K shares derived: sum of 2 quarters · filed 2023-03-06 | 407.27K shares derived: sum of 3 quarters · filed 2023-03-06 | 429.78K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 249.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 254.28K shares derived: sum of 2 quarters · filed 2022-11-10 | 276.80K shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 4.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 27.40K shares 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | 22.51K shares 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |